A detailed history of Temasek Holdings (Private) LTD transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Temasek Holdings (Private) LTD holds 5,355,832 shares of DNLI stock, worth $134 Million. This represents 0.64% of its overall portfolio holdings.

Number of Shares
5,355,832
Holding current value
$134 Million
% of portfolio
0.64%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$20.96 - $31.05 $112 Million - $166 Million
5,355,832 New
5,355,832 $156 Million
Q1 2024

May 15, 2024

SELL
$15.83 - $23.35 $18.8 Million - $27.8 Million
-1,189,647 Reduced 17.25%
5,706,345 $117 Million
Q1 2023

May 15, 2023

BUY
$21.91 - $32.67 $8.32 Million - $12.4 Million
379,951 Added 5.83%
6,895,992 $159 Million
Q4 2022

May 15, 2023

BUY
$26.28 - $33.92 $24.7 Million - $31.9 Million
940,000 Added 16.86%
6,516,041 $181 Million
Q4 2022

Feb 14, 2023

BUY
$26.28 - $33.92 $24.7 Million - $31.9 Million
940,000 Added 16.86%
6,516,041 $181 Million
Q3 2022

May 15, 2023

BUY
$25.97 - $38.53 $5.36 Million - $7.96 Million
206,554 Added 3.85%
5,576,041 $171 Million
Q3 2022

Apr 05, 2023

SELL
$25.97 - $38.53 $24.4 Million - $36.2 Million
-940,000 Reduced 14.43%
5,576,041 $171 Million
Q3 2022

Nov 14, 2022

BUY
$25.97 - $38.53 $5.36 Million - $7.96 Million
206,554 Added 3.85%
5,576,041 $171 Million
Q1 2022

May 15, 2023

SELL
$29.0 - $47.27 $33.3 Million - $54.2 Million
-1,146,554 Reduced 17.6%
5,369,487 $173 Million
Q3 2021

Nov 15, 2021

BUY
$48.48 - $78.23 $46.5 Million - $75 Million
959,030 Added 21.74%
5,369,487 $271 Million
Q4 2017

Feb 14, 2018

BUY
$15.04 - $21.45 $66.3 Million - $94.6 Million
4,410,457
4,410,457 $69 Million

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.36B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Temasek Holdings (Private) LTD Portfolio

Follow Temasek Holdings (Private) LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Temasek Holdings (Private) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Temasek Holdings (Private) LTD with notifications on news.